Login / Signup

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Hans C LeeJatin J ShahLei FengAshley MorpheyRalph J JohnsonEmily T WessonMichael L WangRaymond AlexanianSheeba K ThomasRobert Z OrlowskiDonna M Weber
Published in: American journal of hematology (2019)
Keyphrases
  • multiple myeloma
  • phase iii
  • study protocol
  • phase ii
  • low dose
  • clinical trial
  • high dose
  • randomized controlled trial
  • stem cell transplantation
  • double blind